TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17094981

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ACTH
Number of subjects: 15

Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 15
Study: 16152759

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha 2a (180 microg per week) and RBV (1000‐1200 mg daily)
Number of subjects: 198
Study: 12225445

Group type: EXPERIMENTAL
Intervention: CBT + acamprosate
Number of subjects: 50

Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 50
Study: 10363624

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg without antacid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg with antacid (concomitantly)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg one hour after antacid administration
Number of subjects: 12
Study: 7549753

Group type: EXPERIMENTAL
Intervention: Supplementation with four nutrients (vitamin A, riboflavin, zinc, and selenium), one capsule twice a week for 1 year
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo, one capsule twice a week for 1 year
Number of subjects: 298
Study: 2250565

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: Methysergide
Number of subjects: 8
Study: 6767186

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31943717

Group type: EXPERIMENTAL
Intervention: TAVR with periprocedural anticoagulation with unfractionated heparin
Number of subjects: 800
Study: 31201072

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard consent
Number of subjects: 72
Study: 28235795

Group type: EXPERIMENTAL
Intervention: Culturally tailored parenting support program (Ladnaan) combined with the parenting program Connect, delivered over 12 weeks, 1 to 2 hours each week in groups of 12 to 17 parents.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 120
Study: 26066736

Group type: EXPERIMENTAL
Intervention: Doxorubicin (75 mg/m²) and ifosfamide (2.5 g/m²/d) on days 1-3 with mesna 500 mg/m²/dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gemcitabine (900 mg/m² on days 1, 8) and docetaxel (100 mg/m² on day 8)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Doxorubicin and ifosfamide (AI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gemcitabine and docetaxel (GD)
Number of subjects: 80
Study: 23986139

Group type: EXPERIMENTAL
Intervention: Collaborative learning
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional pre‐clinical teaching
Number of subjects: 54
Study: 21129744

Group type: EXPERIMENTAL
Intervention: Intervention (6 home visits 2-8 weeks postpartum)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control (1 planned visit)
Number of subjects: 295
Study: 19186958

Group type: EXPERIMENTAL
Intervention: Protocol provided scaling and root planing
Number of subjects: 303

Group type: COMPARATOR
Intervention: Community care
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Any preventive or periodontal care
Number of subjects: 303

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 303
Study: 17891452

Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping (group II); 50 patients with 69 PVCs.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional mapping (group I); 50 patients with 65 PVCs.
Number of subjects: 100
Study: 15622454

Group type: EXPERIMENTAL
Intervention: CPG 7909 (0.125, 0.5, or 1.0 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 0
Study: 11260410

Group type: EXPERIMENTAL
Intervention: Fluvastatin (FLU) 40 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study: 9488586

Group type: EXPERIMENTAL
Intervention: Predisposing factors (benefits, motivation, knowledge; Cronbach alpha = 0.50)
Number of subjects: 2764

Group type: EXPERIMENTAL
Intervention: Enabling factors (barriers, norms, social support; Cronbach alpha = 0.55)
Number of subjects: 2764

Group type: EXPERIMENTAL
Intervention: Stage of change for adopting diets lower in fat and higher in fiber/fruits and vegetables
Number of subjects: 2764

Group type: EXPERIMENTAL
Intervention: Dietary intake measures (fat, fiber, fruits and vegetables)
Number of subjects: 2764

Group type: EXPERIMENTAL
Intervention: Multiple regression models including predisposing and enabling factors, stage of change, and covariates
Number of subjects: 2764
Study: 8045978

Group type: EXPERIMENTAL
Intervention: alpha MSH (2.5 mg as an iv bolus 60 min after the start of saline infusion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CRH (ovine CRH infused at 100 micrograms/h for 3 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CRH plus alpha MSH (injected 60 min after the start of CRH infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3143450

Group type: EXPERIMENTAL
Intervention: Orthopaedic geriatric unit
Number of subjects: 222

Group type: COMPARATOR
Intervention: Orthopaedic wards
Number of subjects: 222
Study: 31781760

Group type: EXPERIMENTAL
Intervention: BSFL23
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BSFL29
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BSFL0
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BSFL11
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BSFL18
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Threonine, methionine, and tryptophan
Number of subjects: 24
Study: 30946212

Group type: EXPERIMENTAL
Intervention: Macular ganglion cell-inner plexiform layer (GCIPL) measurements
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Circumferential retinal nerve fiber layer (cpRNFL) measurements
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of GCIPL and cpRNFL
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of GCIPL and cpRNFL in inferior hemifield defect group
Number of subjects: 96
Study: 28286971

Group type: EXPERIMENTAL
Intervention: YOMI program (five-week intervention, twice a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list condition (control group)
Number of subjects: 0
Study: 26587288

Group type: EXPERIMENTAL
Intervention: Hyaluronidase and local anaesthetic
Number of subjects: 70

Group type: COMPARATOR
Intervention: Local anaesthetic only (Control)
Number of subjects: 70
Study: 23615640

Group type: EXPERIMENTAL
Intervention: 1 mg of estradiol (E2) daily for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg of estradiol (E2) and 0.5 mg of norethindrone acetate (NA) daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 60
Study: 22122887

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 355

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 355
Study: 18955387

Group type: EXPERIMENTAL
Intervention: HerpeSelect HSV‐2 ELISA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Kalon HSV‐2 ELISA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Western blot
Number of subjects: 120

Group type: COMPARATOR
Intervention: Recombinant inhibition test
Number of subjects: 120
Study: 16863399

Group type: EXPERIMENTAL
Intervention: Telephone interventions by nursing students for 12 to 14 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Comparison group (no telephone interventions)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Telephone interventions by nursing students
Number of subjects: 2
Study: 15276594

Group type: EXPERIMENTAL
Intervention: Interferon administered three times weekly with weight-based ribavirin
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Daily interferon with weight-based ribavirin
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin therapy
Number of subjects: 661
Study: 15513442

Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 0
Study: 9466164

Group type: EXPERIMENTAL
Intervention: RS-8359, oral dosing up to 300 mg
Number of subjects: 0
Study: 7877116

Group type: EXPERIMENTAL
Intervention: High-risk nonusers (thinking about using steroids)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Low-risk nonusers (not thinking about using steroids)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Steroid users
Number of subjects: 404
Study: 3282481

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (maximum dosage of 300 mg/d, mean dosage at week 8 of 82.8 mg/d)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 29420150

Group type: EXPERIMENTAL
Intervention: LHTLH (normobaric hypoxia; 3,000 m; n=6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: LHTL (normoxia; 0 m; n=6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: LLTL (sea level with regular training only; n=6)
Number of subjects: 18
Study: 27716246

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25698080

Group type: EXPERIMENTAL
Intervention: Image of an overweight individual
Number of subjects: 262

Group type: COMPARATOR
Intervention: Image of a thin individual
Number of subjects: 262
Study: 23091174

Group type: EXPERIMENTAL
Intervention: Static magnetic field at 1.5 T
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Static magnetic field at 3.0 T
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Static magnetic field at 7.0 T
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control condition (mock imager with no magnetic field)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Static magnetic field (varying strengths)
Number of subjects: 41
Study: 20691830

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (tailored information bimonthly for 2 years via telephone)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Nonbehavioral intervention (control group)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 588
Study: 18240203

Group type: EXPERIMENTAL
Intervention: Sequential disease‐modifying antirheumatic drug monotherapy (group 1)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Step‐up combination therapy (group 2)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with tapered high‐dose prednisone (group 3)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab (group 4)
Number of subjects: 508
Study: 17014731

Group type: EXPERIMENTAL
Intervention: Supervised Nordic Walking twice a week for eight weeks under supervision of a specially trained instructor
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic Walking for eight weeks after one training session with an instructor
Number of subjects: 150

Group type: COMPARATOR
Intervention: Advice to stay active (one hour motivational talk)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Supervised Nordic Walking
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic Walking
Number of subjects: 150
Study: 14673036

Group type: EXPERIMENTAL
Intervention: TAD-HAM-TAD maintenance
Number of subjects: 832

Group type: COMPARATOR
Intervention: S-HAM
Number of subjects: 832
Study: 10069525

Group type: EXPERIMENTAL
Intervention: Secretin infusion (0.1 CU/kg.h) for 60 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Secretin + CCK infusion (0.5 IDU/kg.h) for 60 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Secretin infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Secretin + CCK infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Plasma PP levels
Number of subjects: 8
Study: 7501488

Group type: EXPERIMENTAL
Intervention: Polyethylene film dressing with a perimeter adhesive system applied to a randomly determined nipple, present at all times except during feeding.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 50
Study: 2233201

Group type: EXPERIMENTAL
Intervention: 7% carbohydrate‐electrolyte drink (CE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: flavored water placebo (P)
Number of subjects: 10
Study: 836095

Group type: EXPERIMENTAL
Intervention: Operating room with modern ventilation system utilizing HEPA type filters
Number of subjects: 156

Group type: COMPARATOR
Intervention: Surgical suite with no environmental or traffic control systems
Number of subjects: 156
Study: 31359519

Group type: EXPERIMENTAL
Intervention: Crocin 15 mg/day
Number of subjects: 53
Study: 28805758

Group type: EXPERIMENTAL
Intervention: noophen (γ‐amino‐β‐phenylbutyric acid hydrochloride) 15‐20 mg/kg per day (2‐3 times perorally) for 2 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: noophen (γ‐amino‐β‐phenylbutyric acid hydrochloride)
Number of subjects: 30
Study: 26272250

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (FA) administered i.v. 15 min before skin incision in group F.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered i.v. 15 min before skin incision in group C.
Number of subjects: 60
Study: 25109510

Group type: EXPERIMENTAL
Intervention: 800-mg darunavir tablet (test)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 2 × 400-mg darunavir tablets (reference)
Number of subjects: 99
Study: 23107992

Group type: EXPERIMENTAL
Intervention: Novel partner intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention program
Number of subjects: 0
Study: 19528850

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Static Stretch (SS)
Number of subjects: 18
Study: 18160686

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab
Number of subjects: 722

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 722
Study: 15117843

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 0
Study: 11786587

Group type: EXPERIMENTAL
Intervention: Oral megestrol acetate 800 mg/d liquid suspension plus placebo
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Oral dronabinol 2.5 mg twice a day plus placebo
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Combination therapy (dronabinol and megestrol acetate)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Anorexia/Cachexia Therapy questionnaire
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Single‐item Uniscale (global QOL instrument)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 469
Study: 9822841

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 24
Study: 7926080

Group type: EXPERIMENTAL
Intervention: Danazol (400 mg orally twice daily for 4 months)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Estrogen and progestin replacement regimen (for 4 months)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 52
Study: 3302093

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 29066587

Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Non-synchronized noninvasive ventilation (ns‐NIV)
Number of subjects: 15
Study: 27041263

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (prophylactic administration)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-flurbiprofen (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Non-flurbiprofen (MTS group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-flurbiprofen (non-MTS group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: FloTrac sensor
Number of subjects: 57
Study: 23715407

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise training
Number of subjects: 25

Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 25
Study: 23221660

Group type: EXPERIMENTAL
Intervention: Aroma self-foot reflexology massage
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 21374895

Group type: EXPERIMENTAL
Intervention: Chronic low back pain patients
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Patients with high disability and limitations in daily living
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Patients with depression
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Therapeutic procedures and hospital or rehabilitational care
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Overall LBP care costs
Number of subjects: 1378
Study: 19039821

Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19530147

Group type: EXPERIMENTAL
Intervention: XIENCE V stent
Number of subjects: 1002

Group type: COMPARATOR
Intervention: TAXUS stent
Number of subjects: 1002
Study: 16372689

Group type: EXPERIMENTAL
Intervention: Form 1 (brief information about common risks and risk factors associated with IVCM)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Form 2 (comprehensive information about risks and risk factors associated with IVCM)
Number of subjects: 265
Study: 11735758

Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 616

Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 616
Study: 9013219

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation and guided imagery intervention (RG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study: 8736043

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol (CORT) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol (CORT) influence
Number of subjects: 0
Study: 3430589

Group type: EXPERIMENTAL
Intervention: Team competitions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual competition
Number of subjects: 0
Study: 31447131

Group type: EXPERIMENTAL
Intervention: Niacin/Laropiprant (2000/40 mg/d)
Number of subjects: 25673
Study: 28891419

Group type: EXPERIMENTAL
Intervention: Listening to Holy Qur'an recitation in combination with endurance‐resistance training (n = 28)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Endurance‐resistance training only (n = 25)
Number of subjects: 53
Study: 26568566

Group type: EXPERIMENTAL
Intervention: Intermittent ART (I-ART) for 2 years, consisting of 6 month periods on once-daily boosted-PI-based ART, alternating with 6 month periods without ART.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intermittent ART (I-ART) for 2 years.
Number of subjects: 44
Study: 24989409

Group type: EXPERIMENTAL
Intervention: SPECT RNA cluster analysis (normal average approach)
Number of subjects: 49

Group type: COMPARATOR
Intervention: SPECT RNA phase analysis
Number of subjects: 49

Group type: COMPARATOR
Intervention: PET scar size analysis
Number of subjects: 49
Study: 22115984

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19237716

Group type: EXPERIMENTAL
Intervention: Combination treatment with folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d)
Number of subjects: 5205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5205
Study: 18070474

Group type: EXPERIMENTAL
Intervention: Voltage-gated potassium channel current density in ACS patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Kv1.3 protein expression in ACS patients
Number of subjects: 12
Study: 15765890

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 10305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study: 11560871

Group type: EXPERIMENTAL
Intervention: Diltiazem (200 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9934573

Group type: EXPERIMENTAL
Intervention: Local injection of lidocaine hydrochloride
Number of subjects: 15

Group type: COMPARATOR
Intervention: Local injection of saline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 15
Study: 7946688

Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I/ml with NaCl 28 mmol/l
Number of subjects: 117

Group type: COMPARATOR
Intervention: iohexol only
Number of subjects: 117
Study: 3652930

Group type: EXPERIMENTAL
Intervention: Naloxone 12 micrograms/kg i.v.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Coffee (4 cups of Italian style 'espresso' coffee)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Coffee plus naloxone simultaneously
Number of subjects: 5
Study: 29078743

Group type: EXPERIMENTAL
Intervention: Scores + Visual + Force feedback
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Visual + Force feedback
Number of subjects: 14
Study: 27031165

Group type: EXPERIMENTAL
Intervention: Effective microorganism-X (EM-X) supplementation (70 ml·day(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (TEMPPLA or HOTPLA)
Number of subjects: 6
Study: 24873159

Group type: EXPERIMENTAL
Intervention: Shang Ring circumcision by transverse incision in the distal penis foreskin and pull-up of the interior board
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional transverse incision and longitudinal suture of the frenulum praeputii
Number of subjects: 130
Study: 23751149

Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 304
Study: 20078917

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg, 3 times daily as needed for up to 7 days
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg, 3 times daily as needed for up to 7 days
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both ibuprofen and cyclobenzaprine, 3 times daily as needed for up to 7 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 18616688

Group type: EXPERIMENTAL
Intervention: Trazodone (50 to 150 mg at bedtime) for 12 weeks
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173